JP2022506503A5 - - Google Patents
Info
- Publication number
- JP2022506503A5 JP2022506503A5 JP2021523902A JP2021523902A JP2022506503A5 JP 2022506503 A5 JP2022506503 A5 JP 2022506503A5 JP 2021523902 A JP2021523902 A JP 2021523902A JP 2021523902 A JP2021523902 A JP 2021523902A JP 2022506503 A5 JP2022506503 A5 JP 2022506503A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleotides
- antisense strand
- dsrna agent
- sense strand
- strand
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024129696A JP2024149701A (ja) | 2018-11-09 | 2024-08-06 | 修飾二重鎖オリゴヌクレオチド |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862758094P | 2018-11-09 | 2018-11-09 | |
| US62/758,094 | 2018-11-09 | ||
| PCT/US2019/059818 WO2020097044A1 (en) | 2018-11-09 | 2019-11-05 | Modified double stranded oligonucleotides |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024129696A Division JP2024149701A (ja) | 2018-11-09 | 2024-08-06 | 修飾二重鎖オリゴヌクレオチド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022506503A JP2022506503A (ja) | 2022-01-17 |
| JP2022506503A5 true JP2022506503A5 (enExample) | 2022-09-20 |
| JP7536007B2 JP7536007B2 (ja) | 2024-08-19 |
Family
ID=70612465
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021523902A Active JP7536007B2 (ja) | 2018-11-09 | 2019-11-05 | 修飾二重鎖オリゴヌクレオチド |
| JP2024129696A Pending JP2024149701A (ja) | 2018-11-09 | 2024-08-06 | 修飾二重鎖オリゴヌクレオチド |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024129696A Pending JP2024149701A (ja) | 2018-11-09 | 2024-08-06 | 修飾二重鎖オリゴヌクレオチド |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US12600965B2 (enExample) |
| EP (1) | EP3877524A4 (enExample) |
| JP (2) | JP7536007B2 (enExample) |
| AU (2) | AU2019376628B2 (enExample) |
| CA (1) | CA3118537A1 (enExample) |
| WO (1) | WO2020097044A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL288931B2 (en) | 2013-03-14 | 2025-05-01 | Alnylam Pharmaceuticals Inc | Compositions comprising a complementary portion of C5 IRNA and methods of using them |
| TWI851574B (zh) | 2018-05-14 | 2024-08-11 | 美商阿尼拉製藥公司 | 血管收縮素原（ＡＧＴ）ｉＲＮＡ組成物及其使用方法 |
| WO2020097044A1 (en) * | 2018-11-09 | 2020-05-14 | Alnylam Pharmaceuticals, Inc. | Modified double stranded oligonucleotides |
| BR112022009216A2 (pt) * | 2019-11-13 | 2022-08-02 | Alnylam Pharmaceuticals Inc | Métodos e composições para tratar um distúrbio associado a angiotensinogênio (agt) |
| MX2023008469A (es) * | 2021-01-22 | 2023-11-22 | Alnylam Pharmaceuticals Inc | Oligonucleotidos de doble hebra modificados. |
| EP4291654A2 (en) | 2021-02-12 | 2023-12-20 | Alnylam Pharmaceuticals, Inc. | Superoxide dismutase 1 (sod1) irna compositions and methods of use thereof for treating or preventing superoxide dismutase 1- (sod1-) associated neurodegenerative diseases |
| EP4314296A2 (en) | 2021-03-29 | 2024-02-07 | Alnylam Pharmaceuticals, Inc. | Huntingtin (htt) irna agent compositions and methods of use thereof |
| TW202328449A (zh) | 2021-09-24 | 2023-07-16 | 美商艾拉倫製藥公司 | 微管相關蛋白ＴＡＵ（ＭＡＰＴ）ｉＲＮＡ試劑組合物及其使用方法 |
| US11879125B2 (en) | 2022-03-16 | 2024-01-23 | Empirico Inc. | GalNAc compositions for improving siRNA bioavailability |
| AU2023245603A1 (en) | 2022-03-28 | 2024-11-07 | Empirico Inc. | Modified oligonucleotides |
| TW202449152A (zh) * | 2023-02-09 | 2024-12-16 | 美商艾拉倫製藥股份有限公司 | Ｒｅｖｅｒｓｉｒ分子及其使用方法 |
| WO2026046153A1 (zh) * | 2024-08-26 | 2026-03-05 | 倍臻生物技术（苏州）有限公司 | 修饰的双链核糖核酸及其应用 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2011343664B2 (en) * | 2010-12-17 | 2015-10-08 | Arrowhead Pharmaceuticals, Inc. | Galactose cluster-pharmacokinetic modulator targeting moiety for siRNA |
| SI3366775T2 (sl) | 2011-11-18 | 2025-12-31 | Alnylam Pharmaceuticals, Inc. | Modificirana sredstva RNAI |
| EP3730618A1 (en) | 2011-11-18 | 2020-10-28 | Alnylam Pharmaceuticals, Inc. | Rnai agents, compositions and methods of use thereof for treating transthyretin (ttr) associated diseases |
| US9127274B2 (en) | 2012-04-26 | 2015-09-08 | Alnylam Pharmaceuticals, Inc. | Serpinc1 iRNA compositions and methods of use thereof |
| KR102234623B1 (ko) | 2013-05-22 | 2021-04-02 | 알닐람 파마슈티칼스 인코포레이티드 | Ｔｍｐｒｓｓ6 조성물 및 이의 사용 방법 |
| WO2015042564A1 (en) | 2013-09-23 | 2015-03-26 | Alnylam Pharmaceuticals, Inc. | Methods for treating or preventing transthyretin (ttr) associated diseases |
| LT3052628T (lt) | 2013-10-04 | 2020-09-10 | Alnylam Pharmaceuticals, Inc. | Kompozicijos ir būdai alas1 geno raiškai nuslopinti |
| IL316808A (en) * | 2014-08-20 | 2025-01-01 | Alnylam Pharmaceuticals Inc | Modified double-stranded RNA materials and their uses |
| TW202503057A (zh) | 2014-10-10 | 2025-01-16 | 美商艾爾妮蘭製藥公司 | 用於抑制hao1(羥酸氧化酶1(乙醇酸鹽氧化酶))基因表現的組合物及方法 |
| KR102545316B1 (ko) | 2014-11-10 | 2023-06-22 | 알닐람 파마슈티칼스 인코포레이티드 | Ｂ형 간염 바이러스(ｈｂｖ) ｉｒｎａ 조성물 및 그의 이용 방법 |
| JP2017535552A (ja) * | 2014-11-17 | 2017-11-30 | アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | アポリポタンパク質Ｃ３（ＡＰＯＣ３）ｉＲＮＡ組成物およびその使用方法 |
| WO2016085852A1 (en) | 2014-11-24 | 2016-06-02 | Alnylam Pharmaceuticals, Inc. | Tmprss6 irna compositions and methods of use thereof |
| CN115927335A (zh) * | 2015-04-13 | 2023-04-07 | 阿尔尼拉姆医药品有限公司 | 类血管生成素3（ANGPTL3）iRNA组合物及其使用方法 |
| WO2017011286A1 (en) | 2015-07-10 | 2017-01-19 | Alnylam Pharmaceuticals, Inc. | Insulin-like growth factor binding protein, acid labile subunit (igfals) and insulin-like growth factor 1 (igf-1) irna compositions and methods of use thereof |
| PT3329002T (pt) | 2015-07-31 | 2021-01-12 | Alnylam Pharmaceuticals Inc | Composições de iarn de transtirretina (ttr) e métodos de seu uso para tratamento ou prevenção de doenças associadas à ttr |
| CN108348541A (zh) | 2015-08-25 | 2018-07-31 | 阿尔尼拉姆医药品有限公司 | 用于治疗前蛋白转化酶枯草杆菌蛋白酶kexin(pcsk9)基因相关障碍的方法和组合物 |
| US11260134B2 (en) | 2016-09-29 | 2022-03-01 | National University Corporation Tokyo Medical And Dental University | Double-stranded nucleic acid complex having overhang |
| US11504391B1 (en) | 2016-11-23 | 2022-11-22 | Alnylam Pharmaceuticals, Inc. | Modified RNA agents with reduced off-target effect |
| TWI788312B (zh) | 2016-11-23 | 2023-01-01 | 美商阿尼拉製藥公司 | 絲胺酸蛋白酶抑制因子Ａ１ ｉＲＮＡ組成物及其使用方法 |
| WO2018112320A1 (en) | 2016-12-16 | 2018-06-21 | Alnylam Pharmaceuticals, Inc. | Methods for treating or preventing ttr-associated diseases using transthyretin (ttr) irna compositions |
| CA3059446A1 (en) | 2017-04-18 | 2018-10-25 | Alnylam Pharmaceuticals, Inc. | Methods for the treatment of subjects having a hepatitis b virus (hbv) infection |
| EP3652317A1 (en) | 2017-07-13 | 2020-05-20 | Alnylam Pharmaceuticals, Inc. | Lactate dehydrogenase a (ldha) irna compositions and methods of use thereof |
| AU2019239971B2 (en) | 2018-03-21 | 2025-09-11 | Regeneron Pharmaceuticals, Inc. | 17beta-hydroxysteroid dehydrogenase type 13 (HSD17b13) iRNA compositions and methods of use thereof |
| JP7625512B2 (ja) | 2018-08-13 | 2025-02-03 | アルナイラム ファーマシューティカルズ， インコーポレイテッド | Ｂ型肝炎ウイルス（ＨＢＶ）ｄｓＲＮＡ物質組成物およびその使用方法 |
| WO2020097044A1 (en) * | 2018-11-09 | 2020-05-14 | Alnylam Pharmaceuticals, Inc. | Modified double stranded oligonucleotides |
-
2019
- 2019-11-05 WO PCT/US2019/059818 patent/WO2020097044A1/en not_active Ceased
- 2019-11-05 US US17/291,775 patent/US12600965B2/en active Active
- 2019-11-05 AU AU2019376628A patent/AU2019376628B2/en active Active
- 2019-11-05 CA CA3118537A patent/CA3118537A1/en active Pending
- 2019-11-05 EP EP19882543.2A patent/EP3877524A4/en active Pending
- 2019-11-05 JP JP2021523902A patent/JP7536007B2/ja active Active
-
2024
- 2024-08-06 JP JP2024129696A patent/JP2024149701A/ja active Pending
-
2025
- 2025-10-29 AU AU2025259857A patent/AU2025259857A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022506503A5 (enExample) | ||
| JP2020188756A5 (enExample) | ||
| JP2005517452A5 (enExample) | ||
| JP2013535212A5 (enExample) | ||
| JP2006502694A5 (enExample) | ||
| JP2019141097A5 (enExample) | ||
| JP2018512110A5 (enExample) | ||
| JP2009060893A5 (enExample) | ||
| JP2018512041A5 (enExample) | ||
| JP2020500929A5 (enExample) | ||
| JP2005517430A5 (enExample) | ||
| JP2005517432A5 (enExample) | ||
| JP2005517438A5 (enExample) | ||
| JP2017079776A5 (enExample) | ||
| HRP20210612T1 (hr) | Postupci i pripravci za specifičnu inhibiciju glikolat oksidaze (hao1) pomoću dvolančane rnk | |
| WO2015051366A3 (en) | Novel formats for organic compounds for use in rna interference | |
| JP2023504744A5 (enExample) | ||
| JP2024105284A5 (enExample) | ||
| HRP20191232T1 (hr) | Inhibicija, posredovana rna interferencijom, ekspresije gena virusa hepatitisa b (hbv) korištenjem kratkih interferirajućih nukleinskih kiselina (sina) | |
| JP2018512155A5 (enExample) | ||
| JP2016116520A5 (enExample) | ||
| CA2457528A1 (en) | Rna interference mediated inhibition of hepatitis c virus (hcv) gene expression using short interfering nucleic acid (sina) | |
| JP2022511550A5 (enExample) | ||
| WO2004029212A3 (en) | In vivo gene silencing by chemically modified and stable sirna | |
| WO2009054551A3 (en) | Lipid-modified double-stranded rna having potent rna interference effect |